JP2022545083A - パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ - Google Patents

パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ Download PDF

Info

Publication number
JP2022545083A
JP2022545083A JP2022510980A JP2022510980A JP2022545083A JP 2022545083 A JP2022545083 A JP 2022545083A JP 2022510980 A JP2022510980 A JP 2022510980A JP 2022510980 A JP2022510980 A JP 2022510980A JP 2022545083 A JP2022545083 A JP 2022545083A
Authority
JP
Japan
Prior art keywords
neuromelanin
mri
disease
parkinson
time point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022510980A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021034770A5 (https=
JP2022545083A5 (https=
Inventor
サミュエル クラーク，
ヘルナンデス， ギレルモ ホルガ
クリフォード ミルズ キャシディ，
ケネス ウェングラー，
Original Assignee
テラン バイオサイエンシズ， インコーポレイテッド
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク
ザ リサーチ ファウンデーション フォー メンタル ハイジーン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テラン バイオサイエンシズ， インコーポレイテッド, ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク, ザ リサーチ ファウンデーション フォー メンタル ハイジーン インコーポレイテッド filed Critical テラン バイオサイエンシズ， インコーポレイテッド
Publication of JP2022545083A publication Critical patent/JP2022545083A/ja
Publication of JPWO2021034770A5 publication Critical patent/JPWO2021034770A5/ja
Publication of JP2022545083A5 publication Critical patent/JP2022545083A5/ja
Priority to JP2025028218A priority Critical patent/JP2025074118A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/70—Means for positioning the patient in relation to the detecting, measuring or recording means
    • A61B5/702—Posture restraints
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5608—Data processing and visualization specially adapted for MR, e.g. for feature analysis and pattern recognition on the basis of measured MR data, segmentation of measured MR data, edge contour detection on the basis of measured MR data, for enhancing measured MR data in terms of signal-to-noise ratio by means of noise filtering or apodization, for enhancing measured MR data in terms of resolution by means for deblurring, windowing, zero filling, or generation of gray-scaled images, colour-coded images or images displaying vectors instead of pixels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Developmental Disabilities (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
JP2022510980A 2019-08-20 2020-08-17 パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ Withdrawn JP2022545083A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025028218A JP2025074118A (ja) 2019-08-20 2025-02-25 パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889300P 2019-08-20 2019-08-20
US62/889,300 2019-08-20
PCT/US2020/046686 WO2021034770A1 (en) 2019-08-20 2020-08-17 Neuromelanin-sensitive mri for assessing parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025028218A Division JP2025074118A (ja) 2019-08-20 2025-02-25 パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ

Publications (3)

Publication Number Publication Date
JP2022545083A true JP2022545083A (ja) 2022-10-25
JPWO2021034770A5 JPWO2021034770A5 (https=) 2023-08-25
JP2022545083A5 JP2022545083A5 (https=) 2023-08-25

Family

ID=74660631

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022510980A Withdrawn JP2022545083A (ja) 2019-08-20 2020-08-17 パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ
JP2025028218A Pending JP2025074118A (ja) 2019-08-20 2025-02-25 パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025028218A Pending JP2025074118A (ja) 2019-08-20 2025-02-25 パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ

Country Status (10)

Country Link
US (2) US20220273184A1 (https=)
EP (1) EP4018202A4 (https=)
JP (2) JP2022545083A (https=)
KR (2) KR20220100851A (https=)
CN (1) CN114787631A (https=)
AU (1) AU2020334980A1 (https=)
CA (1) CA3151632A1 (https=)
IL (1) IL290693A (https=)
MX (1) MX2022002105A (https=)
WO (1) WO2021034770A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025074118A (ja) * 2019-08-20 2025-05-13 テラン バイオサイエンシズ インコーポレイテッド パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10955423B2 (en) 2015-12-15 2021-03-23 The General Hospital Corporation Methods of estimating blood glucose and related systems
US11293852B2 (en) 2016-04-07 2022-04-05 The General Hospital Corporation White blood cell population dynamics
TWI781463B (zh) * 2020-10-15 2022-10-21 臺北醫學大學 腦部多巴胺轉運體檢查系統及其運作方法
JP2024510080A (ja) * 2021-03-11 2024-03-06 テラン バイオサイエンシズ インコーポレイテッド バイオマーカーを含む撮像データセットのハーモナイゼーションのためのシステム、デバイス及び方法
EP4312729A4 (en) * 2021-04-02 2025-02-26 Spintech, Inc. SYSTEMS AND METHODS FOR TEMPLATE-BASED AUTOMATIC RECOGNITION OF ANATOMICAL STRUCTURES
WO2022266654A1 (en) * 2021-06-16 2022-12-22 The General Hospital Corporation Methods to characterize functional and dysfunctional acute inflammatory responses to pathologic processes
US11911170B2 (en) * 2021-09-13 2024-02-27 Christopher J. Rourk Deep brain sensing and stimulation probe
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
WO2023235766A2 (en) * 2022-05-31 2023-12-07 University Of Ottawa Institute Of Mental Health Research Methods for acquiring and analyzing neuromelanin-sensitive mri
US12599313B2 (en) * 2022-06-23 2026-04-14 ViBo Health LLC Health trackers for autonomous targeting of tissue sampling sites
CN114999657A (zh) * 2022-08-03 2022-09-02 首都医科大学附属北京友谊医院 评估帕金森病患者的神经纤维束与步态障碍的相关性的方法和相关产品
US20260049105A1 (en) * 2022-08-18 2026-02-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss
WO2024081800A1 (en) * 2022-10-12 2024-04-18 Octave Bioscience, Inc. Measuring brain volumes for modeling neurological disease state
CN115735857B (zh) * 2022-11-24 2025-11-18 江苏珂玛麒生物科技有限公司 一种帕金森病动物模型的构建方法
KR102906269B1 (ko) * 2023-08-03 2026-01-02 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법
CN116740064B (zh) * 2023-08-14 2023-10-20 山东奥洛瑞医疗科技有限公司 一种核磁共振肿瘤区域提取方法
CN117372437B (zh) * 2023-12-08 2024-02-23 安徽农业大学 用于面神经麻痹智能化检测与量化方法及其系统
KR102832391B1 (ko) * 2024-08-13 2025-07-14 주식회사 휴런 Mri영상에서 뉴로멜라닌의 탈침착 정량화를 위한 이미지 처리방법 및 그 처리장치
KR102834035B1 (ko) * 2024-08-16 2025-07-21 주식회사 휴런 3d 멀티 에코 gre를 이용한 뉴로멜라닌과 나이그로좀1의 동시 촬영 및 이미지 처리방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
US20150125057A1 (en) * 2012-05-04 2015-05-07 Emory University Methods, systems and computer readable storage media storing instructions for imaging and determining information associated with regions of the brain
JP2016527942A (ja) * 2013-07-02 2016-09-15 サージカル インフォメーション サイエンシズ インコーポレイテッドＳｕｒｇｉｃａｌ Ｉｎｆｏｒｍａｔｉｏｎ Ｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脳画像パイプライン及び脳画像領域の位置及び形状予測のための方法並びにシステム
JP2017517325A (ja) * 2014-06-12 2017-06-29 コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ 拡散強調磁気共鳴イメージングを用いて組織内の鉄の量を定量化するｍｒｉ方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288545B1 (en) * 1999-03-22 2001-09-11 General Electric Company Method and apparatus for calibration of RF and gradient field time delays
EP1332363A4 (en) * 2000-10-09 2007-08-29 Kay Double PROOF OF NEURODEGENERATIVE DISEASES
US20070275944A1 (en) * 2006-04-05 2007-11-29 The Board Of Trustees Operating Michigan State University Antioxidants and methods of their use
WO2016154682A1 (en) * 2015-04-02 2016-10-06 Crc For Mental Health Ltd Method for predicting risk of cognitive deterioration
US11352671B2 (en) * 2015-05-01 2022-06-07 Vanderbilt University Predicting therapeutic response in Parkinson's disease
WO2017053718A2 (en) * 2015-09-23 2017-03-30 Boston Medical Center Corporation Biomarkers for the early detection of parkinson's disease
EP3547252B1 (en) * 2016-12-28 2025-10-22 Shanghai United Imaging Healthcare Co., Ltd. Multi-modal image processing system and method
CN113271985A (zh) * 2018-08-07 2021-08-17 悦智有限公司 用于诊断多巴胺能和运动障碍的方法
US20220273184A1 (en) * 2019-08-20 2022-09-01 Terran Biosciences, Inc. Neuromelanin-sensitive mri for assessing parkinson's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150125057A1 (en) * 2012-05-04 2015-05-07 Emory University Methods, systems and computer readable storage media storing instructions for imaging and determining information associated with regions of the brain
JP2016527942A (ja) * 2013-07-02 2016-09-15 サージカル インフォメーション サイエンシズ インコーポレイテッドＳｕｒｇｉｃａｌ Ｉｎｆｏｒｍａｔｉｏｎ Ｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脳画像パイプライン及び脳画像領域の位置及び形状予測のための方法並びにシステム
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
JP2017517325A (ja) * 2014-06-12 2017-06-29 コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ 拡散強調磁気共鳴イメージングを用いて組織内の鉄の量を定量化するｍｒｉ方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLIFFORD M CASSIDT, ET.AL.,: "Neuralmelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain", PNAS, vol. 116,11, JPN7024001305, 12 March 2019 (2019-03-12), US, pages 5108 - 5117, ISSN: 0005293199 *
KEITA MATSUURA ET AL.: "A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease", NEUROSCIENCE LETTERS, vol. 633, JPN6024012256, 2016, pages 112 - 117, ISSN: 0005445595 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025074118A (ja) * 2019-08-20 2025-05-13 テラン バイオサイエンシズ インコーポレイテッド パーキンソン病を評価するためのニューロメラニン高感度ｍｒｉ

Also Published As

Publication number Publication date
EP4018202A1 (en) 2022-06-29
KR20250110932A (ko) 2025-07-21
CA3151632A1 (en) 2021-02-25
WO2021034770A1 (en) 2021-02-25
AU2020334980A1 (en) 2022-03-03
EP4018202A4 (en) 2023-11-01
CN114787631A (zh) 2022-07-22
JP2025074118A (ja) 2025-05-13
KR20220100851A (ko) 2022-07-18
MX2022002105A (es) 2022-08-04
IL290693A (en) 2022-04-01
US20220273184A1 (en) 2022-09-01
US20260007323A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
US20260007323A1 (en) Neuromelanin-sensitive mri for assessing parkinson's disease
Bangen et al. Cognitive dispersion is a sensitive marker for early neurodegenerative changes and functional decline in nondemented older adults.
Pauls et al. Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition
Walker et al. Lewy body dementias
US11344199B2 (en) Systems and methods for detection and prediction of brain disorders based on neural network interaction
Charlton et al. White-matter tract integrity in late-life depression: associations with severity and cognition
US20230389854A1 (en) Neuromelanin-sensitive mri and methods of use thereof
WO2017172487A1 (en) Detecting or treating post-traumatic stress syndrome
KR20210076055A (ko) 인간 뇌에서의 도파민 기능의 비침습적 대리 척도로서의 신경 멜라닌 감지 자기 공명 이미징을 위한 시스템, 방법 및 컴퓨터 액세스가능 매체
US20230200716A1 (en) Use of neuromelanin-sensitive mri as a biomarker of dopamine function
US10534052B2 (en) FMRI biomarker of neurodegenerative disease
CN116745858A (zh) 神经黑色素敏感性mri及其使用方法
Seewoo In-vivo MRI study of the effects of low-intensity rTMS on brain activity, chemistry and structure in rats.
Mieling Functional and structural changes in the progression of Alzheimer's disease: insights from human imaging
Sassani Investigating energy metabolism in motor neuron disease using phosphorus magnetic resonance spectroscopy
Chumin Cortical Connectivity in Alcoholism
Hawkins Acute Anti-psychotic Modulation of the Structure and Function of the Brain
Beaver et al. INSPIRES-in-patient support program in recovery from stroke-“the voice (s) of experience”
Lidstone Expectation, the placebo effect and Parkinson's disease: an investigation using high-resolution positron emission tomography
Horga et al. Striatal dopamine s nthesis capacit and neuromelanin in the substantia nigra: a multimodal imaging stud in schizophrenia and health controls
Rolinski Clinical and neuroimaging biomarkers of early and prodromal Parkinson's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250311

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250528